 For this purpose, relapsed or refractory MM patients after at least two prior lines of therapy including bortezomib and lenalidomide, who are refractory or intolerant to lenalidomide and refractory to the last line of therapy will be treated with 28-day cycles of Filanesib administered iv as a 1-hour 10-minute infusion at escalating doses on days 1, 2, 15 16, pomalidomide administered po at escalating doses during 21 days with 7 days rest period dexamethasone at a fixed dose of 40 mg po days 1, 8, 15 22. G-CSF prophylaxis is mandatory in all patients after Filanesib, starting from Day 3 and Day 17 for a total of 7 days each. Treatment will be continued until progression or unacceptable toxicity. 